GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLine Rx Ltd (NAS:BLRX) » Definitions » Pretax Margin %

BioLine Rx (BioLine Rx) Pretax Margin % : -289.27% (As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is BioLine Rx Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. BioLine Rx's Pre-Tax Income for the three months ended in Dec. 2023 was $-13.89 Mil. BioLine Rx's Revenue for the three months ended in Dec. 2023 was $4.80 Mil. Therefore, BioLine Rx's pretax margin for the quarter that ended in Dec. 2023 was -289.27%.

The historical rank and industry rank for BioLine Rx's Pretax Margin % or its related term are showing as below:

BLRX' s Pretax Margin % Range Over the Past 10 Years
Min: -1262.84   Med: -1262.84   Max: -1262.84
Current: -1262.84


BLRX's Pretax Margin % is ranked worse than
76.05% of 1027 companies
in the Biotechnology industry
Industry Median: -155.67 vs BLRX: -1262.84

BioLine Rx Pretax Margin % Historical Data

The historical data trend for BioLine Rx's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLine Rx Pretax Margin % Chart

BioLine Rx Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Pretax Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -1,262.81

BioLine Rx Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -289.27

Competitive Comparison of BioLine Rx's Pretax Margin %

For the Biotechnology subindustry, BioLine Rx's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioLine Rx's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioLine Rx's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where BioLine Rx's Pretax Margin % falls into.



BioLine Rx Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

BioLine Rx's Pretax Margin for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-60.615/4.8
=-1,262.81 %

BioLine Rx's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as

Pretax Margin=Pre-Tax Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-13.885/4.8
=-289.27 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioLine Rx  (NAS:BLRX) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


BioLine Rx Pretax Margin % Related Terms

Thank you for viewing the detailed overview of BioLine Rx's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


BioLine Rx (BioLine Rx) Business Description

Traded in Other Exchanges
Address
2 HaMa’ayan Street, Modi’in, ISR, 7177871
BioLine Rx Ltd is a pre-commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

BioLine Rx (BioLine Rx) Headlines

From GuruFocus

BioLineRx to Report First Quarter 2023 Results on May 24, 2023

By PRNewswire PRNewswire 05-17-2023